David Hargreaves
Overview
Explore the profile of David Hargreaves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Milne J, Qian C, Hargreaves D, Wang Y, Wilson J
PLoS One
. 2023 Mar;
18(3):e0282562.
PMID: 36893084
Using a relatively small training set of ~16 thousand images from macromolecular crystallisation experiments, we compare classification results obtained with four of the most widely-used convolutional deep-learning network architectures that...
12.
Petrovic D, Scott J, Bodnarchuk M, Lorthioir O, Boyd S, Hughes G, et al.
J Chem Inf Model
. 2022 Aug;
62(16):3832-3843.
PMID: 35920716
ROS1 rearrangements account for 1-2% of non-small cell lung cancer patients, yet there are no specifically designed, selective ROS1 therapies in the clinic. Previous knowledge of potent ROS1 inhibitors with...
13.
Orozco C, Bersellini M, Irving L, Howard W, Hargreaves D, Devine P, et al.
MAbs
. 2022 Jul;
14(1):2095701.
PMID: 35799328
Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding...
14.
Finlay M, Barton P, Bickerton S, Bista M, Colclough N, Cross D, et al.
J Med Chem
. 2021 Sep;
64(18):13704-13718.
PMID: 34491761
The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including...
15.
Ricks M, Belward P, Hargreaves D
J Wrist Surg
. 2021 Jun;
10(3):224-228.
PMID: 34109065
Midcarpal instability is a term for a collection of poorly understood conditions where the proximal row of the carpus is unstable. The most common type of midcarpal instability is palmar...
16.
Wilson J, Ristic M, Kirkwood J, Hargreaves D, Newman J
iScience
. 2020 Jun;
23(6):101219.
PMID: 32540772
In macromolecular crystallization, success is often dependent on the pH of the experiment. However, little is known about the pH of reagents used, and it is generally assumed that the...
17.
Luptak J, Bista M, Fisher D, Flavell L, Gao N, Wickson K, et al.
Acta Crystallogr D Struct Biol
. 2019 Nov;
75(Pt 11):1003-1014.
PMID: 31692474
Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is...
18.
Mukherjee H, Su N, Belmonte M, Hargreaves D, Patel J, Tentarelli S, et al.
Bioorg Med Chem Lett
. 2019 Oct;
29(23):126682.
PMID: 31606346
Over the last ten years, targeted covalent inhibition has become a key discipline within medicinal chemistry research, most notably in the development of oncology therapeutics. One area where this approach...
19.
Tron A, Belmonte M, Adam A, Aquila B, Boise L, Chiarparin E, et al.
Nat Commun
. 2018 Dec;
9(1):5341.
PMID: 30559424
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance...
20.
Nimrod G, Fischman S, Austin M, Herman A, Keyes F, Leiderman O, et al.
Cell Rep
. 2018 Nov;
25(8):2121-2131.e5.
PMID: 30463010
The ultimate goal of protein design is to introduce new biological activity. We propose a computational approach for designing functional antibodies by focusing on functional epitopes, integrating large-scale statistical analysis...